Pfizer Inc. secured China's approval for its obesity drug ecnoglutide, a GLP-1 receptor agonist developed through a $495 million deal with Hangzhou Sciwind Bioscience. The therapy, targeting chronic weight management in adults, positions Pfizer as a late entrant into a rapidly expanding market dominated by Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. Both rivals face patent expirations this year, risking price wars as generic competitors emerge.

The drug, derived from Sciwind's research, showed 15.4% average weight loss in trials, comparable to Mounjaro. Unlike Wegovy, Sciwind's formulation emphasizes safety and efficacy, with a modified structure targeting GLP-1 receptors. Pfizer plans to leverage Sciwind's local expertise while retaining Sciwind's development responsibilities. Analysts note the move aligns with Pfizer's $10 billion acquisition of Metsera to strengthen its obesity portfolio.

China's approval accelerates Pfizer's strategy to compete in a market projected to reach $100 billion by 2030. However, Wegovy's generic influx later this month could disrupt pricing dynamics. Novo Nordisk and Eli Lilly have already reduced drug prices to fend off generic threats, signaling intensified competition. Pfizer's CEO, Albert Bourla, called the deal critical for "aggressive market entry" in China's "booming" obesity sector.

The drug's approval underscores the sector's saturation and the race for first-mover advantage. With generics looming, companies must balance innovation with cost pressures. Pfizer's partnership model—marketing Sciwind's asset while maintaining collaborative R&D—may set a template for future obesity drug launches in emerging markets.